We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 7 for:    Connect mm
Previous Study | Return to List | Next Study

Connect® MM- The Multiple Myeloma Disease Registry

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01081028
First Posted: March 5, 2010
Last Update Posted: August 28, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Celgene
March 4, 2010
March 5, 2010
August 28, 2017
September 1, 2009
December 31, 2024   (Final data collection date for primary outcome measure)
  • Identify and summarize patterns in therapeutic regimens [ Time Frame: up to 8 years ]
    Describe practice patterns of common first-line treatment regimens and subsequent therapeutic strategies in patients newly diagnosed with symptomatic MM in the community and academic setting
  • Identify and summarize patterns in therapeutic regimens and patient outcomes [ Time Frame: up to 8 years ]
    Provide insight into treatment regimens and therapy sequence in clinical practice as they relate to clinical outcomes (response, overall survival, progression-free survival) in patients newly diagnosed with symptomatic MM
Same as current
Complete list of historical versions of study NCT01081028 on ClinicalTrials.gov Archive Site
  • Summarize Effectiveness of Treatment Regimens [ Time Frame: up to 8 years ]
    Describe any differences in effectiveness associated with different treatment regimens, including common first-line regimens, subsequent therapeutic strategies and regional effects (such as proximity of academic centers) in patients newly diagnosed with symptomatic MM
  • Summarize health-related quality of life (HRQoL) relation to treatment regimens/sequence and clinical outcomes [ Time Frame: up to 8 years ]
    Describe the health-related quality of life (HRQoL) of patients newly diagnosed with symptomatic MM, and to explore the association with HRQoL of treatment regimens/sequence and clinical outcomes
Same as current
Not Provided
Not Provided
 
Connect® MM- The Multiple Myeloma Disease Registry
Connect® MM- The Multiple Myeloma Disease Registry
The purpose of the Connect® MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) and provide unique insights into the management of MM and the impact of this hematologic disorder on patients.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients with multiple myoloma and being treated in community or academic settings.
Multiple Myeloma
Not Provided
  • Group One: Patients enrolled between Sep2009 and Nov2011
    Newly diagnosed multiple myeloma patients enrolled between Sep 2009 and Nov 2011.
  • Group Two: Patients enrolled between Dec2012 and mid-2016
    Newly diagnosed multiple myeloma patients enrolled between Dec 2012 and mid-2016

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
3011
December 31, 2024
December 31, 2024   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Newly diagnosed with symptomatic MM within 2 months of enrollment in Connect®MM registry
  • Age ≥18 years
  • Willing and able to provide signed informed consent
  • Agrees to complete patient assessment questionnaires either alone or with minimal assistance from caregivers and/or trained site personnel

Exclusion Criteria:

- None

Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Puerto Rico,   United States
 
 
NCT01081028
Connect ® MM
No
Not Provided
Not Provided
Celgene
Celgene
Not Provided
Study Director: Mohamad Hussein, MD Celgene Corporation
Celgene
August 2017